

Andreas Verras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11171843/publications.pdf>

Version: 2024-02-01

25
papers

405
citations

687363

13
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

647
citing authors

#	ARTICLE	IF	CITATIONS
1	Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1 <i>H</i> -benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3594-3605.	6.4	65
2	Computer-Assisted Design of Selective Imidazole Inhibitors for Cytochrome P450 Enzymes. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3572-3579.	6.4	48
3	QSAR Prediction of Passive Permeability in the LLC <i>PK1</i> Cell Line: Trends in Molecular Properties and Cross-Prediction of Caco-2 Permeabilities. <i>Molecular Informatics</i> , 2012, 31, 231-245.	2.5	27
4	Cytochrome P450 active site plasticity: attenuation of imidazole binding in cytochrome P450cam by an L244A mutation. <i>Protein Engineering, Design and Selection</i> , 2006, 19, 491-496.	2.1	23
5	Discovery of Benzimidazole CYP11B2 Inhibitors with <i>in Vivo</i> Activity in Rhesus Monkeys. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 573-578.	2.8	21
6	MAIP: a web service for predicting blood-stage malaria inhibitors. <i>Journal of Cheminformatics</i> , 2021, 13, 13.	6.1	20
7	Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1299-1305.	2.2	19
8	Discovery of Triazole CYP11B2 Inhibitors with <i>in Vivo</i> Activity in Rhesus Monkeys. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 861-865.	2.8	17
9	Informing the Selection of Screening Hit Series with <i>in Silico</i> Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6771-6780.	6.4	17
10	Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2384-2388.	2.2	17
11	Peptidomic profiling of human cerebrospinal fluid identifies YPRPIHPA as a novel substrate for prolylcarboxypeptidase. <i>Proteomics</i> , 2010, 10, 2882-2886.	2.2	15
12	The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 658-665.	2.2	15
13	Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 445-453.	5.4	15
14	Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1657-1660.	2.2	14
15	Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 128-132.	2.8	12
16	Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1774-1778.	2.2	10
17	Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6228-6233.	2.2	9
18	Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1550-1556.	2.2	7

#	ARTICLE	IF	CITATIONS
19	A new class of prolylcarboxypeptidase inhibitors, Part 2: The aminocyclopentanes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2818-2822.	2.2	7
20	A new class of prolylcarboxypeptidase inhibitors, Part 1: Discovery and evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2811-2817.	2.2	6
21	Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1380-1385.	2.2	6
22	Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1727-1730.	2.2	5
23	Synthesis of oxaspiropiperidines as a strategy for lowering logD. <i>Tetrahedron Letters</i> , 2011, 52, 6457-6459.	1.4	4
24	Chapter 10 Cytochrome P450 Enzymes: Computational Approaches to Substrate Prediction. <i>Annual Reports in Computational Chemistry</i> , 2006, 2, 171-195.	1.7	3
25	Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1182-1186.	2.2	3